Drugs / TQB2922
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07260708 | Dec 2025 → Dec 2029 expected | cancer of unknown primary site | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06188624 | Feb 2024 → Dec 2026 expected | — | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07844187 | Oct 2026 → Aug 2027 expected | colorectal cancer | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07601204 | Jun 2026 → Feb 2029 expected | head and neck cancer | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07044908 | Jul 2025 → Jul 2026 overdue | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2922 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260708 ↗ |
| Action | Inhibit | “TQB2922 blocks the activation of EGFR and c-Met signalling pathway” NCT07044908 ↗ |
| Route | Intravenous | “TQB2922 is administered in the appropriate dose group, intravenously” NCT07044908 ↗ |
| Target | EGFR | “binding to EGFR and c-Met on the surface of tumour cells” NCT07044908 ↗ |
| Target | MET | “binding to EGFR and c-Met on the surface of tumour cells” NCT07044908 ↗ |